A randomized, open-label clinical trial to evaluate immunogenicity and safety of an indigenously developed DTwP-Hib tetravalent combination vaccine (Easyfour®-TT) with Quadrovax® in Indian infants-Reference-Cited by-同舟云学术

A randomized, open-label clinical trial to evaluate immunogenicity and safety of an indigenously developed DTwP-Hib tetravalent combination vaccine (Easyfour®-TT) with Quadrovax® in Indian infants

Published:2017-07-12 Issue:9 Volume:13 Page:2025-2031
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Mohanty Lalitendu¹,Sharma Sunil¹,Behera Beauty¹,Panwar Sachin¹,Paliwal Charu¹,Singh Anit¹,Gupta Anu¹,Chilkoti Deepak Chandra¹

Affiliation:

1. Clinical Research Department, Panacea Biotec Ltd., G-3, B-1 Extn/ Mohan Co-op, New Delhi, Delhi, India

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2017.1342020

Reference26 articles.

1. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine

2. Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants

3. Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers

4. Use of Combination Vaccines Is Associated With Improved Coverage Rates

5. The Use of Combination Vaccines Has Improved Timeliness of Vaccination in Children

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost‐minimization analysis of DTaP‐IPV‐Hib combination vaccine in China: A nationwide cross‐sectional study;Journal of Medical Virology;2022-12-05

2. Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6–8, 10–12, and 14–16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study;Vaccine: X;2022-12